Progress in the medical treatment of epilepsy: an overview of new antiepileptic drugs

Sabers, Anne; Gram, Lennart

doi:10.1111/j.1468-1331.1995.tb00072.x

Cited by 4 publications

(3 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other known interactions of CBZ with other antiepileptic drugs (AED), the macrolide group of antibiotics, cimetidine, dextropropoxiphen and warfarin are not of concern with this one [14][15][16][17]. When used together with lamotrigine (LTG), another of the new drugs, the patients may complain of side effects of blurred vision or dizziness due to a pharmacodynamic interaction between both drugs [11]. Another strategy followed mainly by specialists in the treatment of the disease is to use from the beginning the more appropriate drug for the syndrome or the type of epilepsy diagnosed.…”

Section: Oxcarbazepinementioning

confidence: 97%

“…Oxcarbazepine (OXC) derives from CBZ and it has the same indications, is better tolerated and interacts less with other drugs than the mother drug [11]. However OXC keeps the same problems as the other enzyme inducing drugs when used together with the contraceptive pill.…”

Section: Oxcarbazepinementioning

confidence: 99%

“…Gabapentin is absorbed through a saturable active transport in the gut and it may be even more active if larger doses are tried than those used in the clinical trials, possibly without significant increase of side effects [11].…”

Section: Gabapentinementioning

confidence: 99%

See 2 more Smart Citations

The New Drugs and the Strategies to Manage Epilepsy

Lima

2000

CPD

View full text Add to dashboard Cite

After a short historical review of the development of the pharmaceutical treatment of the epilepsies the author reviews some of the possible strategies to manage patients with the different types of epilepsies and epileptic syndromes using the classical drugs. A strategy used by most of the physicians uses Sodium Valproate as the first line drug for almost all patients. This may be replaced by other drugs according to their efficacy against the different types of seizures to be treated whenever VPA has not enough efficacy or isn t well tolerated. On the other hand epileptologists use the different drugs according to the different epilepsies and epileptic syndromes depending on the relative efficacy of each drug available and the possible side effects. He then describes succinctly the better-known new drugs and makes some comments on the coming drugs now in development. Finally he proceeds to include them in the strategies above described. Lamotrigine and possibly Topiramate are good candidates to replace VPA in the one drug strategy. Lamotrigine, Oxcarbamazepine and possibly Gabapentin may be used in the future as 1st line drugs in selected patients. Vigabatrin is already used as one of the better alternatives for West syndrome and Oxcarbamazepine has replaced Carbamazepine in countries where it s available to the public. Some drawbacks have been apparent with these drugs like the hepatic and haematological toxic effect of Felbamate or the apparently irreversible fields constriction provoked by Vigabatrin, which did limit their use.

show abstract

Section: Oxcarbazepinementioning

confidence: 97%

Section: Oxcarbazepinementioning

confidence: 99%

See 1 more Smart Citation

The New Drugs and the Strategies to Manage Epilepsy

Lima

2000

CPD

View full text Add to dashboard Cite

show abstract

Vigabatrin withdrawal randomized study in children

1996

View full text Add to dashboard Cite

Untitled

Cupello

Scarrone

2001

Neurochemical Research

View full text Add to dashboard Cite

Pretreatment with 100 microM GABA of synaptosomes purified from rat brain results in an increased uptake of the labelled neurotransmitter in subsequent incubations. The effect is blocked by a GABA(B) receptor antagonist, 2-hydroxy-saclofen. The effect is mimicked by baclofen and the baclofen effect is blocked by saclofen too. Lower GABA concentrations (up to 50 microM) do not result in an increase of subsequent GABA uptake. Treatment of synaptosomes with 8-Br-cAMP results in a decreased GABA uptake. Since the uptake incubations were run with saturating concentrations of labelled GABA, the data indicates that GABA(B) receptor activation in brain synaptosomes up-regulates their GABA uptake capacity by an increase in Vmax. This mechanism appears of physiological relevance under conditions of sustained GABA release and substantial increase of its extracellular concentration.

show abstract

Progress in the medical treatment of epilepsy: an overview of new antiepileptic drugs

Cited by 4 publications

References 102 publications

The New Drugs and the Strategies to Manage Epilepsy

The New Drugs and the Strategies to Manage Epilepsy

Vigabatrin withdrawal randomized study in children

Untitled

Contact Info

Product

Resources

About